New Antibody-Drug Conjugate Payload Bypasses Resistance
The research-stage agent avoids common drug efflux mechanisms, showing complete response in animal tumor models.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Do you believe developing novel cancer drug mechanisms is a high priority for improving health?
Ryvu Therapeutics has presented preclinical in-vivo data for RVU602, a proprietary antibody-drug conjugate (ADC) payload. This research-stage platform operates independently of existing topoisomerase I and microtubule inhibitor mechanisms to bypass tumor resistance.
Why it matters
Current ADC payloads often share underlying mechanisms that lead to drug efflux and cross-resistance in tumors. By utilizing a distinct pathway, RVU602 aims to overcome these limitations and reduce toxicity in next-generation oncology treatments.
The RVU602 payload exhibits a 6-8 drug-to-antibody ratio with >95% monomeric content and <1% payload release in mouse plasma. Across 272 tested cancer cell lines, transcriptomic profiling confirmed the agent induces neither replication-stress nor mitotic-arrest signatures.
The players
Ryvu Therapeutics
A biotechnology company headquartered in Kraków, Poland, specializing in the development of small-molecule oncology therapies and proprietary ADC platforms.
The details
RVU602 is an antibody-drug conjugate payload—a targeted therapy where a cytotoxic drug is chemically linked to an antibody—designed to trigger the release of extracellular ATP to kill cancer cells. Unlike standard payloads that rely on topoisomerase I (an enzyme involved in DNA replication) or microtubule inhibitors (agents that block cell division), RVU602 avoids P-gp-mediated drug efflux, a cellular process that pumps out therapeutic agents. Researchers successfully conjugated the payload to anti-TROP2, anti-EGFR, anti-c-MET, and anti-HER2 antibodies to validate its versatile targeting capabilities.
Timeline
October 14, 2026: Ryvu Therapeutics presented the RVU602 poster at the World ADC Congress.
Q1 2027: Planned start of a Phase II study for the candidate drug dapolsertib.
The Tech Race
The development of RVU602 follows a broader industry trend to diversify payload classes beyond traditional topoisomerase I and microtubule inhibitors. Ryvu Therapeutics is positioning this platform as an alternative to overcome documented cross-resistance in existing ADC clinical pipelines.
As this payload remains in preclinical development, it is not yet available for clinical use or oncology patient care. The company’s immediate research milestones are focused on validating these results before pursuing human clinical trials.
The takeaway
The study suggests that RVU602 could effectively bypass common drug efflux mechanisms that limit the efficacy of current ADC treatments. Clinicians and investors should track Ryvu Therapeutics’ upcoming clinical program developments for further validation of this payload in human subjects.
Further reading
For more on the current state of antibody-drug development, visit our Biotech section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe developing novel cancer drug mechanisms is a high priority for improving health?
